CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy

• Published in: Anticancer research Vol. 37; no. 2; pp. 935 - 940
• Main Authors: Sone, Kazuki, Oguri, Tetsuya, Nakao, Makoto, Kagawa, Yusuke, Kurowaka, Ryota, Furuta, Hiromi, Fukuda, Satoshi, Uemura, Takehiro, Takakuwa, Osamu, Kanemitsu, Yoshihiro, Ohkubo, Hirotsugu, Takemura, Masaya, Maeno, Ken, Ito, Yutaka, Sato, Hidefumi, Muramatsu, Hideki, Niimi, Akio
• Format: Journal Article
• Language: English
• Published: Greece 01-02-2017
• Subjects: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm - blood; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomarkers, Tumor - blood; Carcinoembryonic Antigen - blood; Carcinoma, Non-Small-Cell Lung - blood; Carcinoma, Non-Small-Cell Lung - diagnosis; Carcinoma, Non-Small-Cell Lung - drug therapy; Disease-Free Survival; Female; Humans; Keratin-19 - blood; Lung Neoplasms - blood; Lung Neoplasms - diagnosis; Lung Neoplasms - drug therapy; Male; Middle Aged; Multivariate Analysis; Outcome Assessment (Health Care) - methods; Outcome Assessment (Health Care) - statistics & numerical data; Pemetrexed - administration & dosage; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; pemetrexed; non-squamous non-small cell lung cancer; tumor marker; Cytokeratin 19 fragment
• DOI: 10.21873/anticanres.11402
• EISSN: 1791-7530
• ISSN: 0250-7005

Pretreatment serum tumor marker levels predict outcome in non-small cell lung cancer (NSCLC). However, little is known about the clinical value of such measurements for patients treated with pemetrexed plus a platinum-derivative.
We retrospectively screened 100 chemotherapy-naïve patients with advanced non-squamous NSCLC treated with pemetrexed plus a platinum-derivative in relation to the pretreatment level of cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA).
Sixty one patients with a high CYFRA 21-1 level had statistically shorter progression-free and overall survival than 39 patients with a normal CYFRA 21-1 level (median progression-free survival=127 days vs. 191 days, respectively; p=0.046; median overall survival=360 days vs. 781 days, respectively, p<0.001). Serum CEA level was not related to survival.
Serum CYFRA 21-1 level is a predictive and prognostic marker in patients with NSCLC treated with pemetrexed plus a platinum-derivative.